Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.
Novo Nordisk is facing increased competition in the GLP-1 receptor agonist market, a class of drugs used to treat type 2 diabetes and obesity. Eli Lilly has been gaining ground with its own GLP-1 drug, tirzepatide, which has shown promising results in clinical trials. This development has significant implications for Novo Nordisk, which has traditionally been a leader in the GLP-1 market with its semaglutide franchise.
The competition between Novo Nordisk and Eli Lilly is likely to have a significant impact on the global obesity market, which is expected to continue growing in the coming years. As the market expands, pharmaceutical companies are positioning themselves to capture a larger share of the market. Eli Lilly's advantages, including its diversified portfolio and strong research and development capabilities, may give it an edge in the competition.
Currency investors should watch the performance of Novo Nordisk's semaglutide franchise and the progress of Eli Lilly's tirzepatide in the coming quarters. Any significant changes in market share or sales growth could impact the Danish kroner, as Novo Nordisk is one of the country's largest companies and a major contributor to Denmark's GDP. Additionally, investors should keep an eye on the US dollar, as Eli Lilly's performance in the US market will be an important factor in determining the company's overall success.
Originally reported by cnbc.com. CurrencyNews adds analysis for finance & markets readers.